Experienced in Liver Failure

Dr. Wen J. Xie

Public Health and Preventive Medicine
600 Army Navy Dr, 
Arlington, VA 
Experienced in Liver Failure
600 Army Navy Dr, 
Arlington, VA 
OverviewInsuranceLocationsClinical Research

Overview

Wen Xie is a Public Health and Preventive Medicine provider in Arlington, Virginia. Dr. Xie is rated as an Experienced provider by MediFind in the treatment of Liver Failure. Her top areas of expertise are Liver Failure, Gallbladder Disease, and Vitrectomy.

Her clinical research consists of co-authoring 351 peer reviewed articles and participating in 8 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 9 articles in the study of Liver Failure.

Specialties
Public Health and Preventive Medicine
Licenses
Preventive Medicine/Occupational Environmental Medicine in VA
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Group Health Cooperative
  • HMO
  • POS
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO

Locations

600 Army Navy Dr, Arlington, VA 22202

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

8 Clinical Trials

Phase IIb Multi-Center, Randomised, Partial-Blind Parallel Cohort Study to Assess the Efficacy and Safety of Treatment With GSK3228836 in Participants With Chronic Hepatitis B Virus (B-Clear)
Phase IIb Multi-Center, Randomised, Partial-Blind Parallel Cohort Study to Assess the Efficacy and Safety of Treatment With GSK3228836 in Participants With Chronic Hepatitis B Virus (B-Clear)
Enrollment Status: Completed
Publish Date: May 16, 2023
Intervention Type: Drug
Study Drugs: GSK3228836, Nucleos(t)ide therapy
Study Phase: Phase 2
Precise Prediction System for Clinical Endpoint Events of Chronic Hepatitis B Patients in the Ear of Antiviral Therapy
Precise Prediction System for Clinical Endpoint Events of Chronic Hepatitis B Patients in the Ear of Antiviral Therapy
Enrollment Status: Active_not_recruiting
Publish Date: September 06, 2022
Effect of Entecavir Treatment on Regression and Long-term Disease Outcome in Patients With HBV-induced Liver Fibrosis and Cirrhosis (Regress Extension Study)
Effect of Entecavir Treatment on Regression and Long-term Disease Outcome in Patients With HBV-induced Liver Fibrosis and Cirrhosis (Regress Extension Study)
Enrollment Status: Active_not_recruiting
Publish Date: April 28, 2021
Intervention Type: Drug
Study Drug: Entecavir
Study Phase: Phase 4
A Double-Blind, Placebo-Controlled Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Ascending Dose and Multiple Doses of GSK3389404 in Chronic Hepatitis B Subjects
A Double-Blind, Placebo-Controlled Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Ascending Dose and Multiple Doses of GSK3389404 in Chronic Hepatitis B Subjects
Enrollment Status: Completed
Publish Date: October 01, 2020
Intervention Type: Drug
Study Phase: Phase 2
Tenofovir Disoproxil Fumarate in Combination of Hepatitis B Vaccine With the Omission of Immune Globulin to Prevent Hepatitis B Transmission in Mother With High Viral Load: A Multi-Center, Prospective, Randomized and Open-Label Study
Tenofovir Disoproxil Fumarate in Combination of Hepatitis B Vaccine With the Omission of Immune Globulin to Prevent Hepatitis B Transmission in Mother With High Viral Load: A Multi-Center, Prospective, Randomized and Open-Label Study
Enrollment Status: Unknown
Publish Date: December 12, 2019
Intervention Type: Drug
Study Drug: Tenofovir Disoproxil Fumarate 
Study Phase: Phase 4
Optimized Treatment and Regression of HBV-induced Liver Fibrosis
Optimized Treatment and Regression of HBV-induced Liver Fibrosis
Enrollment Status: Completed
Publish Date: July 27, 2018
Intervention Type: Drug
Study Phase: Phase 4
Optimized Treatment and Regression of HBV-induced Early Cirrhosis
Optimized Treatment and Regression of HBV-induced Early Cirrhosis
Enrollment Status: Completed
Publish Date: July 27, 2018
Intervention Type: Drug
Study Phase: Phase 4
Optimized Treatment and Regression of HBV-induced Compensated Liver Cirrhosis
Optimized Treatment and Regression of HBV-induced Compensated Liver Cirrhosis
Enrollment Status: Completed
Publish Date: July 27, 2018
Intervention Type: Drug
Study Phase: Phase 4
View 7 Less Clinical Trials

350 Total Publications

Synergistic Control of Megalurothrips usitatus through Sequential RNAi Targeting Novel Lethal Genes and Serratia marcescens HvSm-1.
Synergistic Control of Megalurothrips usitatus through Sequential RNAi Targeting Novel Lethal Genes and Serratia marcescens HvSm-1.
Journal: Journal of agricultural and food chemistry
Published: October 08, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Xie's expertise for a condition
ConditionClose
        Want to save this doctor for later?
        Sign Up
        Is this your doctor?
        Find A Second Opinion
        Not sure about your diagnosis?
        Check Your Symptoms
         
         
         
         
        Learn about our expert tiers
        Learn More
        Are you the provider on this profile?
        Claim Profile